Payment overview · 2025
General Payments
$2,740.51
137 reported records · 21 companies
Healthcare provider profile · identity verified
Charles S Pewitt, DO
Allopathic & Osteopathic Physicians|Family Medicine · JACKSON, MO · NPI 1740389980
Verified facts
What the public records show
CMS Open Payments records show Charles S Pewitt, DO received $2,740.51 in general payments during 2025 across 137 reported records.
ABBVIE INC. accounted for 34.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Rexulti, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $955.38 | 34.9% | 45 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $357.89 | 13.1% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $270.49 | 9.9% | 13 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $197.43 | 7.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $146.67 | 5.3% | 12 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $109.33 | 4.0% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $90.38 | 3.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $74.63 | 2.7% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.42 | 2.6% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.13 | 2.5% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $66.69 | 2.4% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $56.53 | 2.1% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $56.24 | 2.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $54.79 | 2.0% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.48 | 1.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.36 | 1.3% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $22.74 | 0.8% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $17.67 | 0.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.94 | 0.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.39 | 0.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $13.93 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,740.51 | 137 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $587.02 | 27 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $357.89 | 20 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $197.67 | 8 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $197.43 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $184.49 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $137.71 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $129.57 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $116.56 | 6 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $109.33 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $86.26 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $74.63 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $72.42 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $71.92 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $70.65 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $67.13 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $66.69 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $60.41 | 7 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $60.41 | 7 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $56.53 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $56.24 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.85 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $54.13 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $45.48 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $42.32 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.08 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $30.00 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 22 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 131 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 107 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 178 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 51 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
107 | 29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
178 | 31 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
131 | 29 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
178 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
131 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 1109 | 154 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 844 | 103 |
| Lisinopril | Lisinopril | 608 | 155 |
| Simvastatin | Simvastatin | 584 | 156 |
| Levothyroxine Sodium | Levothyroxine Sodium | 516 | 116 |
| Atorvastatin Calcium | Atorvastatin Calcium | 488 | 117 |
| Pantoprazole Sodium | Pantoprazole Sodium | 465 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 437 | 110 |
| Hydrochlorothiazide | Hydrochlorothiazide | 424 | 109 |
| Gabapentin | Gabapentin | 418 | 90 |
| Metformin Hcl | Metformin Hcl | 363 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 339 | 84 |
| Tramadol Hcl | Tramadol Hcl | 335 | 62 |
| Meloxicam | Meloxicam | 324 | 85 |
| Allopurinol | Allopurinol | 315 | 72 |
| Omeprazole | Omeprazole | 298 | 75 |
| Furosemide | Furosemide | 297 | 79 |
| Escitalopram Oxalate | Escitalopram Oxalate | 281 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 278 | 67 |
| Potassium Chloride | Potassium Chloride | 276 | 64 |
| Warfarin Sodium | Warfarin Sodium | 266 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 252 | 36 |
| Lorazepam | Lorazepam | 248 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 243 | 49 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 238 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 65 |
| Famotidine | Famotidine | 211 | 48 |
| Diazepam | Diazepam | 201 | 31 |
| Clonazepam | Clonazepam | 189 | 28 |
| Jardiance | Empagliflozin | 178 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 178 | 46 |
| Montelukast Sodium | Montelukast Sodium | 177 | 48 |
| Carvedilol | Carvedilol | 174 | 44 |
| Glimepiride | Glimepiride | 174 | 34 |
| Diclofenac Potassium | Diclofenac Potassium | 169 | 74 |
| Diclofenac Sodium | Diclofenac Sodium | 169 | 44 |
| Prednisone | Prednisone | 166 | 101 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 164 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 159 | 53 |
| Celecoxib | Celecoxib | 148 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 139 | 36 |
| Spironolactone | Spironolactone | 138 | 34 |
| Losartan Potassium | Losartan Potassium | 135 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 42 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 134 | 15 |
| Eliquis | Apixaban | 131 | 29 |
| Pregabalin | Pregabalin | 127 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 117 | 34 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 111 | 12 |
| Alendronate Sodium | Alendronate Sodium | 109 | 30 |
| Farxiga | Dapagliflozin Propanediol | 107 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 103 | 76 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | 21 |
| Amoxicillin | Amoxicillin | 99 | 81 |
| Methocarbamol | Methocarbamol | 95 | 36 |
| Trazodone Hcl | Trazodone Hcl | 94 | 21 |
| Sertraline Hcl | Sertraline Hcl | 93 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 90 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 88 | 62 |
| Testosterone Cypionate | Testosterone Cypionate | 88 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 85 | 21 |
| Estradiol | Estradiol | 83 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 82 | 24 |
| Fenofibrate | Fenofibrate | 80 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 78 | 19 |
| Buspirone Hcl | Buspirone Hcl | 74 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 73 | 13 |
| Temazepam | Temazepam | 73 | suppressed |
| Xarelto | Rivaroxaban | 70 | 12 |
| Carisoprodol | Carisoprodol | 68 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 14 |
| Eszopiclone | Eszopiclone | 67 | 12 |
| Ibuprofen | Ibuprofen | 67 | 16 |
| Azithromycin | Azithromycin | 66 | 59 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 62 | 16 |
| Propranolol Hcl | Propranolol Hcl | 61 | 13 |
| Clonidine Hcl | Clonidine Hcl | 59 | 14 |
| Donepezil Hcl | Donepezil Hcl | 59 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 59 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 19 |
| Glipizide | Glipizide | 58 | 17 |
| Baclofen | Baclofen | 56 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 56 | 16 |
| Atenolol | Atenolol | 54 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 52 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 17 |
| Ramipril | Ramipril | 52 | suppressed |
| Linzess | Linaclotide | 51 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 39 |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 49 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 12 |
| Naproxen | Naproxen | 48 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Valsartan | Valsartan | 47 | 13 |
| Entresto | Sacubitril/Valsartan | 46 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 11 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 27 |
| Bupropion Xl | Bupropion Hcl | 43 | 12 |
| Meclizine Hcl | Meclizine Hcl | 43 | suppressed |
| Topiramate | Topiramate | 43 | 11 |
| Torsemide | Torsemide | 43 | 14 |
| Cephalexin | Cephalexin | 42 | 22 |
| Gemfibrozil | Gemfibrozil | 42 | 11 |
| Terazosin Hcl | Terazosin Hcl | 42 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 40 | suppressed |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 14 |
| Ozempic | Semaglutide | 39 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | 15 |
| Fluconazole | Fluconazole | 37 | 20 |
| Dutasteride | Dutasteride | 36 | suppressed |
| Finasteride | Finasteride | 36 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Methotrexate | Methotrexate Sodium | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | suppressed |
| Glyburide | Glyburide | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 27 |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 31 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | 11 |
| Vraylar | Cariprazine Hcl | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | suppressed |
| Nystatin | Nystatin | 28 | 12 |
| Liothyronine Sodium | Liothyronine Sodium | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 18 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | 12 |
| Verapamil Hcl | Verapamil Hcl | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 22 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Cefprozil | Cefprozil | 17 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 13 |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,740.51 · 137 records | ABBVIE INC. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, CREON, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, JARDIANCE, LINZESS, LOREEV XR, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, SPRAVATO, TAVNEOS, TRELEGY ELLIPTA, UBRELVY, UZEDY, VOQUEZNA, VRAYLAR, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error